4-Cl-MAR Stats & Data

— Justification: Potency and batch variability. Multiple user reports show widely different active doses (from ~50 mg doing little to 150–200 mg being ‘functional/euphoric’) and some batches likely mislabelled or degraded; therefore allergy testing and slow titration are essential. Reagent testing (e.g., Marquis) may show no reaction for aminorex analogues, so a ‘negative’ test does not confirm identity; lab drug checking (GC/LC‑MS) is preferred.

— Justification: Serotonergic interaction risk. Classic aminorex is a serotonin transporter substrate; combining SERT‑active stimulants or MAOIs raises serotonin syndrome risk. TripSit lists MAOIs and serotonergic combinations with stimulants/DXM/tramadol as dangerous. Avoid these combinations with 4C‑MAR unless under medical supervision.

— Justification: Pulmonary arterial hypertension (PAH) signal for the aminorex class. Aminorex use in 1960s Europe was linked to a marked increase in primary pulmonary hypertension; modern summaries still list aminorex among drug causes of PAH. Frequency and translatability to 4C‑MAR are unknown, but anyone with cardiac/pulmonary risk factors should avoid repeated/frequent use and seek care for unexplained dyspnea, chest pain, near‑syncope, or edema.

— Justification: Potential neurotoxicity concerns by analogy. Para‑chloro substituted phenethylamines (e.g., p‑chloroamphetamine) produce serotonergic neurotoxicity in animals; 4C‑MAR is structurally different (aminorex vs. phenethylamine), so this is an inference rather than a proven risk, but it supports minimizing dose/frequency.

— Justification: Hyperthermia/vasoconstriction and cardiovascular strain are core stimulant risks. Maintain normal hydration (not excessive), take cooling breaks, and avoid stacking stimulants. TripSit stimulant pages document tachycardia, hypertension and peripheral vasoconstriction as typical; users of related halogenated aminorexes also report long wakefulness, jaw tension and big pupils.

— Justification: Long duration and insomnia. 4‑MAR has 10–16 h primary effects with long after‑effects; user reports for 4C‑MAR/4F‑MAR describe 12–20+ h of stimulation or wakefulness, so plan dose timing to avoid sleep loss and avoid redosing late in the day.

— Justification: ROA‑specific cautions. Users describe large hard crystals; insufflation can be irritating and promotes compulsive redosing. Oral dosing has a slower onset but is easier to titrate and may reduce nasal injury; always begin with an allergy test (≤1–5 mg) and increase in small steps using accurate scales/volumetric methods.

— Justification: Testing limitations and misidentification. Aminorex analogues may show little/no reaction with Marquis; therefore a combination of multiple reagents plus access to community drug‑checking services is advised when possible.

— Justification: Space use to limit tolerance and harm. General stimulant guidance recommends substantial breaks between sessions; frequent multi‑day runs accelerate tolerance and sleep/cardiovascular strain.